Novel Dental Gel as an Adjunct to Scaling and Root Planing
University of Alabama at Birmingham · NCT05384132
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–85 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 76
- US sites recruiting
- 1
- Study start
- October 14, 2022
- Record last updated
- December 17, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study will evaluate the use of Livionex Dental Gel (LDG) as a home care product in reducing probing pocket depth (PD) beyond the effect achieved by the current standard of care with SRP in periodontitis patients.
Being studied: SRP + Livfresh Dental Gel; SRP + standard flouride dentifrice
Conditions: Periodontal Diseases; Gingival Diseases; Gingival Pocket; Gum Bleed; Plaque, Dental
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male or female subjects at least 18 years of age.
- Subject must be willing and able to provide written informed consent.
- Available during the course of the study.
- Must have minimum of 20 natural teeth, excluding third molars.
- Must have at least 20 BOP sites, excluding third molars.
- Stage II or III, Grade B periodontitis with at least 4 teeth with a minimum PD of 5 mm and minimum CAL of 3mm.
- No antibiotic therapy for periodontal disease or chronic use of anti-inflammatory drugs (NSAIDs) within the past month of Baseline, or during the study.
- Must not have received definitive treatment (i.e., SRP or periodontal surgical therapy) for periodontitis in the last one year.
- Subject must be willing and able to comply with study visits as described in the protocol.
- Subjects must be available for follow up on the telephone.
- Able to read and understand the consent form in English
Exclusion Criteria
- • Pregnancy or breast feeding.
- Medical condition that requires pre-medication prior to dental procedures.
- Systemic conditions and use of medications that may affect periodontal tissues.
- Severe dental disease characterized multiple decayed, untreated dental sites.
- Presence of orthodontic appliances.
- Diseases of oral soft or hard tissues.
- Participating in another clinical trial currently or in the month preceding this study.
- Stage IV and/or Grade C periodontitis.
- Vertical bone defects 4mm or greater.
- Subjects who have active dental infections other than periodontitis that will require dental treatment during the study period.
- Excessive oral hygiene practices including use of water irrigation devices such as Waterpik or use of interdental cleansers more than twice daily.
- Non-English speaking
- Smokers, uncontrolled or brittle diabetics, HIV/AIDS, and subjects with severe systemic disease, e.g., cancer, lupus, pemphigus vulgaris/pemphigoid, or other oral mucous membrane diseases that would interfere with performance of oral hygiene, e.g., erosive lichen planus, recurrent major aphthous lesions, etc.
- History of allergic reaction to any ingredient in the test/control dentifrices.
- Presence of any condition, abnormality, or situation at Baseline that in the opinion of the Principal Investigator may preclude the subject's ability to comply with study requirements, including completion of the study or the quality of the data.
- Subjects unwilling to use manual toothbrush during the study.
Recruiting US locations
Unversity of Alabama at Birmingham, School of Dentistry
Birmingham, AL 35294-0007
Site contact: Maninder Kaur, BDS,MPH,MS · 205-934-4506 · maninder@uab.edu
Study contacts (from the official record)
- Maninder Kaur, BDS,MPH,MS · 2059344506 · maninder@uab.edu
- Sarah Startley, DMD · 2059758711 · ss1971@uab.edu
Similar studies in Alabama
All healthy volunteers studies in Alabama →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Gadsden, AL + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Regeneron Pharmaceuticals
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)
Merck Sharp & Dohme LLC
- Location
- Anniston, AL
- Eligibility basics
- Ages 18–65